Get the Stockscreener App
2.35
1.29%
0.03
After Hours:
2.23
-0.12
-5.11%
Enveric Biosciences Inc stock is traded at $2.35, with a volume of 67,877.
It is up +1.29% in the last 24 hours and down -47.01% over the past month.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
See More
Previous Close:
$2.32
Open:
$2.26
24h Volume:
67,877
Relative Volume:
0.08
Market Cap:
$3.27M
Revenue:
-
Net Income/Loss:
$-15.08M
P/E Ratio:
-0.366
EPS:
-6.42
Net Cash Flow:
$-11.56M
1W Performance:
+5.86%
1M Performance:
-47.01%
6M Performance:
-86.49%
1Y Performance:
-90.76%
1-Day Range:
$2.12
$2.35
1-Week Range:
$1.98
$2.47
52-Week Range:
$1.96
$37.20
Enveric Biosciences Inc Stock (ENVB) Company Profile
Name
Enveric Biosciences Inc
Sector
Industry
Phone
239-302-1707
Address
245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE
Compare ENVB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
2.35 | 3.23M | 0 | -15.08M | -11.56M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Enveric Biosciences Inc Stock (ENVB) Latest News
Weekly Trades: Can SUUN sustain earnings growthMarket Growth Summary & Weekly Return Optimization Plans - baoquankhu1.vn
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent - Investing News Network
Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises - Asianet Newsable
Biopharmaceutical company Enveric Biosciences announced today that Gilgamesh Pharmaceuticals has officially withdrawn its post-grant review request for a patent previously filed against Enveric Biosciences. - Bitget
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested - Benzinga
Market Review: Does ARIS have declining or rising EPSMarket Movers & Reliable Breakout Forecasts - baoquankhu1.vn
Enveric Biosciences reports EB-003 receptor engagement assay data - Yahoo Finance
Is Enveric Biosciences Inc.’s ROE strong enoughGDP Growth & Growth Focused Stock Pick Reports - mfd.ru
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data - Investing News Network
Enveric’s lead drug candidate activates key pathways linked to depression relief - Investing.com Canada
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy - microdose.buzz
Enveric Biosciences (ENVB) stock: gains as EB-003 shows dual 5-HT₂A pathway activation - parameter.io
Enveric's EB-003 Assay Data Shows Dual 5-HTA Pathway Engagement; Stock Up - Nasdaq
Enveric Biosciences stock soars after revealing new data on lead drug candidate - Investing.com Australia
Enveric Stock Surges After Licensed Trademark Deal - timothysykes.com
Enveric Biosciences (ENVB) Reveals Promising Data on Lead Candidate EB-003 - GuruFocus
Enveric Advances Lead Drug With New Findings On Key Brain Receptor Signals - Benzinga
US Market Recap: What makes Enveric Biosciences Inc stock attractive todayJuly 2025 Institutional & Risk Managed Investment Entry Signals - baoquankhu1.vn
Will Enveric Biosciences Inc. stock outperform Dow Jones indexWeekly Loss Report & Safe Entry Point Identification - mfd.ru
What makes Enveric Biosciences Inc. stock attractive to growth funds2025 Technical Patterns & Expert Approved Trade Ideas - mfd.ru
Can Enveric Biosciences Inc. lead its sector in growthQuarterly Risk Review & Comprehensive Market Scan Insights - mfd.ru
Enveric Biosciences Nears Key Clinical Milestone with Novel Drug Candidate - AD HOC NEWS
Enveric Biosciences (ENVB) Files for Share Sale to Investors - GuruFocus
Why Enveric Biosciences Inc. stock remains on buy listsJuly 2025 Snapshot & Pattern Based Trade Signal System - mfd.ru
US Market Wrap: Is PEBK benefiting from innovation trendsMarket Volume Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Enveric Biosciences Expands At-The-Market Equity Offering Capacity - The Globe and Mail
Growth Report: What is Enveric Biosciences Incs book value per shareWeekly Trade Review & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Can Enveric Biosciences Inc sustain its profitabilityJobs Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Analyst Calls: Is Enveric Biosciences Inc a good ESG investmentQuarterly Market Summary & Safe Capital Investment Plans - baoquankhu1.vn
Fed Meeting: Can Magnite Inc grow without external fundingJuly 2025 Reactions & Verified Momentum Watchlists - baoquankhu1.vn
Enveric Biosciences registers $1.35 million in new shares under ATM agreement - Investing.com UK
Enveric Biosciences registers $1.35 million in new shares under ATM agreement By Investing.com - Investing.com India
Enveric Biosciences Registers Additional Shares for ATM Offering - TradingView
Enveric Biosciences (NASDAQ:ENVB) Trading Down 7.4% – Should You Sell? - Defense World
How does Enveric Biosciences Inc. score in quality rankingsAnalyst Upgrade & Free Weekly Chart Analysis and Trade Guides - mfd.ru
Enveric Biosciences Inc. (ENVB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Enveric licenses RCANN trademark portfolio to TOTEC Pharma By Investing.com - Investing.com South Africa
Enveric Biosciences (ENVB) Licenses Trademark Portfolio to Totec Pharma - GuruFocus
Enveric Biosciences closes $1.5 million registered direct offering By Investing.com - Investing.com Australia
Is Enveric Biosciences Inc. being accumulated by smart money2025 Earnings Impact & Daily Technical Stock Forecast Reports - mfd.ru
Enveric licenses RCANN trademark portfolio to TOTEC Pharma - Investing.com
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option - Chartmill
Enveric Biosciences Announces Closing Of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - TradingView
Enveric Biosciences Raises Capital Through Equity Offering - TipRanks
Enveric Biosciences closes $1.5 million registered direct offering - Investing.com
Enveric Biosciences Signs Securities Purchase Agreement With Institutional Investors - TradingView
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Caledonian Record
Enveric to sell 328,802 shares at $4.41 in registered direct offering - TipRanks
Enveric Biosciences raises $1.5 million in registered direct offering By Investing.com - Investing.com Canada
Enveric Biosciences (ENVB) Announces Stock and Warrant Offering - GuruFocus
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Business Wire
Enveric Biosciences Inc Stock (ENVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):